These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22235098)

  • 61. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
    Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
    Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
    Pacey S; Wilson RH; Walton M; Eatock MM; Hardcastle A; Zetterlund A; Arkenau HT; Moreno-Farre J; Banerji U; Roels B; Peachey H; Aherne W; de Bono JS; Raynaud F; Workman P; Judson I
    Clin Cancer Res; 2011 Mar; 17(6):1561-70. PubMed ID: 21278242
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation.
    Fukumoto R; Kiang JG
    Radiat Res; 2011 Sep; 176(3):333-45. PubMed ID: 21663398
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Hsp90 inhibitor 17-DMAG decreases infection of porcine circovirus type 2 in mice.
    Liu J; You J; Zhang X; Ma C; Dong M; Chen L; Jiang P; Yun S
    Microb Pathog; 2017 Aug; 109():248-252. PubMed ID: 28602838
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 66. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
    Hertlein E; Wagner AJ; Jones J; Lin TS; Maddocks KJ; Towns WH; Goettl VM; Zhang X; Jarjoura D; Raymond CA; West DA; Croce CM; Byrd JC; Johnson AJ
    Blood; 2010 Jul; 116(1):45-53. PubMed ID: 20351313
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 17-DMAG, an HSP90 Inhibitor, Ameliorates Multiple Organ Dysfunction Syndrome via Induction of HSP70 in Endotoxemic Rats.
    Wang YL; Shen HH; Cheng PY; Chu YJ; Hwang HR; Lam KK; Lee YM
    PLoS One; 2016; 11(5):e0155583. PubMed ID: 27224288
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 17-Dimethylaminoethylamino-17-demethoxygeldanamycin attenuates inflammatory responses in experimental stroke.
    Qi J; Han X; Liu HT; Chen T; Zhang JL; Yang P; Bo SH; Lu XT; Zhang J
    Biol Pharm Bull; 2014; 37(11):1713-8. PubMed ID: 25366476
    [TBL] [Abstract][Full Text] [Related]  

  • 69. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
    Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
    Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.
    Smith-Jones PM; Solit D; Afroze F; Rosen N; Larson SM
    J Nucl Med; 2006 May; 47(5):793-6. PubMed ID: 16644749
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells.
    Zhang J; Li H; Huang Z; He Y; Zhou X; Huang T; Dai P; Duan D; Ma X; Yin Q; Wang X; Liu H; Chen S; Zou F; Chen X
    Cell Stress Chaperones; 2016 Mar; 21(2):339-48. PubMed ID: 26786409
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.
    Kim YM; Pyo H
    DNA Cell Biol; 2012 Jan; 31(1):15-29. PubMed ID: 21830942
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
    Chandarlapaty S; Scaltriti M; Angelini P; Ye Q; Guzman M; Hudis CA; Norton L; Solit DB; Arribas J; Baselga J; Rosen N
    Oncogene; 2010 Jan; 29(3):325-34. PubMed ID: 19855434
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Anticancer effect of 17-(6-cinnamamido-hexylamino-)-17-demethoxygeldanamycin: in vitro and in vivo].
    Li L; Liu H; Zhang SH; Hu L; Zhen YS
    Yao Xue Xue Bao; 2013 Dec; 48(12):1771-7. PubMed ID: 24689233
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Heat shock protein 90 inhibitor enhances apoptosis by inhibiting the AKT pathway in thermal-stimulated SK-MEL-2 human melanoma cell line.
    Shin MK; Jeong KH; Choi H; Ahn HJ; Lee MH
    J Dermatol Sci; 2018 Jun; 90(3):357-360. PubMed ID: 29433909
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.
    Song D; Chaerkady R; Tan AC; García-García E; Nalli A; Suárez-Gauthier A; López-Ríos F; Zhang XF; Solomon A; Tong J; Read M; Fritz C; Jimeno A; Pandey A; Hidalgo M
    Mol Cancer Ther; 2008 Oct; 7(10):3275-84. PubMed ID: 18852131
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.
    Kawabe M; Mandic M; Taylor JL; Vasquez CA; Wesa AK; Neckers LM; Storkus WJ
    Cancer Res; 2009 Sep; 69(17):6995-7003. PubMed ID: 19690146
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
    Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
    Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
    Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.